ReviewCNS neuroscience & therapeutics2009
Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium.
Review in CNS neuroscience & therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02129348 (Treatment of Psychosis and Agitation in Alzheimer's Disease), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Psychosis and Agitation in Alzheimer's Disease
Who cites it
21 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review.Molecules (Basel, Switzerland) · 2022Review
- The Impact of Lithium on Brain Function in Bipolar Disorder: An Updated Review of Functional Magnetic Resonance Imaging Studies.CNS drugs · 2021Review
- Hormonal and biochemical changes in female Proechimys guyannensis, an animal model of resistance to pilocarpine-induced status epilepticus.Scientific reports · 2020Article
- Dual Role of Autophagy in Diseases of the Central Nervous System.Frontiers in cellular neuroscience · 2019Review
- L-F001, a Multifunction ROCK Inhibitor Prevents 6-OHDA Induced Cell Death Through Activating Akt/GSK-3beta and Nrf2/HO-1 Signaling Pathway in PC12 Cells and Attenuates MPTP-Induced Dopamine Neuron Toxicity in Mice.Neurochemical research · 2017Article
- Neuroprotective effect of lithium after pilocarpine-induced status epilepticus in mice.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2017Article
- A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts.Neuropsychiatric disease and treatment · 2016Review
- Indirubin-3-Oxime Effectively Prevents 6OHDA-Induced Neurotoxicity in PC12 Cells via Activating MEF2D Through the Inhibition of GSK3β.Journal of molecular neuroscience : MN · 2015Article
- Long-Term Lithium Treatment Increases cPLA₂ and iPLA₂ Activity in Cultured Cortical and Hippocampal Neurons.Molecules (Basel, Switzerland) · 2015Article
- Calcium-dependent intracellular signal pathways in primary cultured adipocytes and ANK3 gene variation in patients with bipolar disorder and healthy controls.Molecular psychiatry · 2015Article
- Glial pathology in bipolar disorder: potential therapeutic implications.CNS neuroscience & therapeutics · 2015Review
- Carvedilol attenuates 6-hydroxydopamine-induced cell death in PC12 cells: involvement of Akt and Nrf2/ARE pathways.Neurochemical research · 2014Article
- Therapeutic benefits of delayed lithium administration in the neonatal rat after cerebral hypoxia-ischemia.PloS one · 2014Article
- Lithium: a versatile tool for understanding renal physiology.American journal of physiology. Renal physiology · 2013Review
- Potential mechanisms of action of lithium in bipolar disorder. Current understanding.CNS drugs · 2013Review
- Off label use of lithium in the treatment of Huntington's disease: A case series.Indian journal of psychiatry · 2013Article
- Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.Frontiers in bioscience (Elite edition) · 2012Review
- Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.Current Alzheimer research · 2012Review
- Midlife predictors of Alzheimer's disease.Maturitas · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lithium is a monovalent cation that was introduced in 1949 by John Cade for the treatment of bipolar disorder. Clinical reports and subsequent studies confirmed this application and the beneficial effects of this compound. However, over the last 15 years, various authors have also demonstrated the neuroprotective effects of lithium against several neurotoxic paradigms. Thus, experimental studies in neuronal cell cultures and animal models of Alzheimer disease and others pathologies have provided strong evidence for the potential benefits of lithium. The main mechanism underlying its neuroprotective effects is thought to be inhibition of glycogen synthase kinase-3 (GSK-3), although other biochemical pathways in the brain could also be affected. In this review, the main mechanisms of lithium action are summarized, including the modulation of glutamate receptors, effects on arachidonic acid metabolism, its role with respect to AKT, and other potential mechanisms. In addition, its effects on neuroprotective proteins such as Bcl-2 and p53 are also discussed. Although the cellular and molecular biological effects of lithium may constitute an effective therapeutic strategy for Alzheimer disease, further clinical and experimental studies with this drug and specific GSK-3 inhibitors are necessary to confirm the use of lithium in therapeutic approaches to neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.